These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10681562)

  • 1. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
    Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
    J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers.
    Samarasinghe SP; Sutanto MM; Danos AM; Johnson DN; Brady MJ; Cohen RN
    Obesity (Silver Spring); 2009 May; 17(5):965-72. PubMed ID: 19165156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
    Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.
    Bruemmer D; Berger JP; Liu J; Kintscher U; Wakino S; Fleck E; Moller DE; Law RE
    Eur J Pharmacol; 2003 Apr; 466(3):225-34. PubMed ID: 12694805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.
    Park Y; Freedman BD; Lee EJ; Park S; Jameson JL
    Diabetologia; 2003 Mar; 46(3):365-77. PubMed ID: 12687335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.
    Yu C; Markan K; Temple KA; Deplewski D; Brady MJ; Cohen RN
    J Biol Chem; 2005 Apr; 280(14):13600-5. PubMed ID: 15691842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.
    Lee G; Elwood F; McNally J; Weiszmann J; Lindstrom M; Amaral K; Nakamura M; Miao S; Cao P; Learned RM; Chen JL; Li Y
    J Biol Chem; 2002 May; 277(22):19649-57. PubMed ID: 11877444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
    Berger J; Tanen M; Elbrecht A; Hermanowski-Vosatka A; Moller DE; Wright SD; Thieringer R
    J Biol Chem; 2001 Apr; 276(16):12629-35. PubMed ID: 11278270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
    Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
    J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance.
    Chatterjee VK
    Biochem Soc Trans; 2001 May; 29(Pt 2):227-31. PubMed ID: 11356159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
    Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
    Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.
    Semple RK; Meirhaeghe A; Vidal-Puig AJ; Schwabe JW; Wiggins D; Gibbons GF; Gurnell M; Chatterjee VK; O'Rahilly S
    Endocrinology; 2005 Apr; 146(4):1871-82. PubMed ID: 15661858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARgamma2 in 3T3-L1 cells.
    Masugi J; Tamori Y; Kasuga M
    Biochem Biophys Res Commun; 1999 Oct; 264(1):93-9. PubMed ID: 10527847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
    Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
    J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.
    Masugi J; Tamori Y; Mori H; Koike T; Kasuga M
    Biochem Biophys Res Commun; 2000 Feb; 268(1):178-82. PubMed ID: 10652233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
    Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
    Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
    Burgermeister E; Tencer L; Liscovitch M
    Oncogene; 2003 Jun; 22(25):3888-900. PubMed ID: 12813462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma and chicken ovalbumin upstream promoter transcription factor II negatively regulate the phosphoenolpyruvate carboxykinase promoter via a common element.
    Eubank DW; Duplus E; Williams SC; Forest C; Beale EG
    J Biol Chem; 2001 Aug; 276(32):30561-9. PubMed ID: 11399762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22.
    Gupta RA; Sarraf P; Brockman JA; Shappell SB; Raftery LA; Willson TM; DuBois RN
    J Biol Chem; 2003 Feb; 278(9):7431-8. PubMed ID: 12468551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.